Session 5: Incidental Findings in the Clinic
DR. WAGNER: And welcome everybody back.
This panel is assembled like our prior panel, except focusing in the area of ‑‑ in the clinical context. And again, we're delighted to have three speakers representing three different perspectives here.
And our first speaker is Haavi Morreim ‑‑ am I saying that ‑‑ it's good enough? You know not to challenge me from my prior ‑‑ and she is professor in the department of internal medicine in the College of Medicine at the University of Tennessee.
DR. GUTMANN: We have a tradition now after hearing from each of you individually, we find it's really helpful to have a roundtable so we can discuss among ourselves and hear from each of you advice that you would have for us on the report that we will do.
The tradition is to ask each of you, we will go down the line starting with Robert.
If there is one specific issue that we address or one specific recommendation or finding that you would advise us to include in our report, what would that be?
SESSION 3: INCIDENTAL FINDINGS IN RESEARCH
DR. GUTMANN: We are going to make a quick transition to our next panel.
DR. WAGNER: Please, Drs. London, Bandettini and Hilgenberg, please come forward. I said that wrong! Bandettini. I apologize.
It is my privilege to introduce this next panel to the Commission. This is the first of the panels that Lisa described to us, where we will be able to hear from an ethicist, a practitioner, and someone whose incidental findings were reflected in some unique way.
DR. GUTMANN: So our first panel this morning, we're going to hear about the ethical challenges of emerging technologies quite generally and how these challenges can inform our understanding and approach to the topic of incidental findings. We'll hear from each speaker for ten minutes and then we're going to open the session for questions and discussions. A quick reminder. When you speak, make sure you've turned your mike on and the red light will come on. And we will begin with our first speaker, Dr.
DR. GUTMANN: Good morning, everyone. I am Amy Gutmann. I'm president of the University of Pennsylvania and chair of the Presidential Commission for the Study of Bioethical Issues. And on behalf of myself and my vice chair, Jim Wagner, I welcome you all to this, our 13th meeting. Before we continue, I want to note the presence of our designated federal official, Commission Executive Director Lisa Lee. Lisa, could you please stand? Great.
SESSION 2: MEMBER DISCUSSION
SESSION 5: MEMBER DISCUSSION
DR. GUTMANN: Good morning, everybody, I'm Amy Gutmann. I’m President of the University of Pennsylvania and Chair of the Presidential Commission for the Study of Bioethical Issues, and I welcome you all here to day two of our 12th meeting of this Commission and happy to do so on behalf of myself and Vice Chair of the Commission and President of Emory University, President Jim Wagner.
SESSION 3: MEMBER DISCUSSION
DR. GUTMANN: I’m going to ask our commission members to assemble so we can get started, and welcome everybody back from lunch.
SESSION 4: PHILOSOPHICAL GROUNDING OF THE ETHICAL APPROACH
DR. WAGNER: Let's all gather.
Okay, I believe all who are available here are assembled, and Dr. Beauchamp will join us by video conference. Tom, can you see and hear us?
DR. BEAUCHAMP: Yes, I can see and hear you.
SESSION 6: FUTURE TOPICS--INCIDENTAL FINDINGS
DR. WAGNER: Welcome back, Commissioners. We're about to commence on our final session and what we want to do is talk about a specific future topic, obviously there are many we could pursue, but as you will see, I think we have a special interest, if not obligation to be looking at a future topic on Incidental Findings.
This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply